StockData

22nd Century vs cbdMD

XXII and YCBD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How XXII and YCBD compare

cbdMD is the larger company, worth 13 times as much as 22nd Century ($4.1M against $312K).

cbdMD grew revenue faster over the last twelve months (10.0% versus −27.4% for 22nd Century).

cbdMD keeps more of each dollar of sales as profit, with a net margin of −13.8% compared with −27.0% at 22nd Century.

cbdMD scores higher on the StockData Score (10 against 6 for 22nd Century), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricXXIIYCBD
Size and price
Market cap$312K$4.1M
Share price$0.437$0.364
Change, 1 year−100.0%−43.3%
Change, 5 years−100%−99.9%
Beta (5Y)–2.27
Employees3242
StockData Score
Total score610 (better)
Valuation score33
Growth score11
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S0.0× (better)0.2×
P/B0.0× (better)0.5×
FCF yield−2806%−59.1% (better)
Fair value$34.80$1.95
Margin of safety98.7% (better)81.4%
Growth
Revenue growth (TTM)−27.4%10.0% (better)
Revenue growth, 5Y average−9.0% (better)−14.5%
Profitability
Gross margin45.0%57.7% (better)
Operating margin−85.0%−13.9% (better)
Net margin−27.0%−13.8% (better)
FCF margin−60.3%−11.5% (better)
Return on equity−32.4% (better)−40.3%
Return on invested capital−106%−41.2% (better)
Financial health
Debt / equity–0.00
Interest coverage−21.5×–
Current ratio2.61 (better)2.50
Altman Z-score−22.20−17.58 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.3%8.2%
Held by insiders35.8%34.6%
Insider net buying, 12 months–−$1.3M
Short interest, % of float262%6.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.